NASDAQ · VNDA

Vanda Pharmaceuticals Inc.

$5.18 -$0.18 (-3.36%) 1D After hours

Key Metrics

$322.33M
Market cap
P/E · TTM
$217.78M
Revenue · TTM
−$239.55M
Net income
EPS · TTM $-4.09
Dividend yield
Free cash flow −$127.30M
Beta · 1Y 1.33
EBITDA · TTM −$148.56M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Mar 10 high, the share price fell 46%.

    Peak close $9.56 on Mar 10; trough close $5.18 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -46%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 23
    The stock moved +41.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 23
  • Feb 12
    The stock moved -17.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$322.33M
Enterprise value
Shares outstanding60.1M
52-wk range$4.14 – $9.94
Avg volume · 20D823.5K
Net cash
Book value / share$4.80
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Vanda Pharmaceuticals Inc.
IPO dateApr 12, 2006
Employees533

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.48
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -68.7%
Net -110.0%
FCF -58.5%
ROE / ROIC -58.5% · -105.7%

Financial Health

Current ratio2.16
Quick ratio2.15
Debt / equity
Debt / EBITDA
Net cash
Working capital$157.59M

Cash Flow · TTM

Operating CF −$126.51M
Capex −$783.00K
Free cash flow −$127.30M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-0.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings